BUZZ-Amarin rises as heart drug spotlighted at major cardiology meet

Reuters04-08
BUZZ-Amarin rises as heart drug spotlighted at major cardiology meet

** Shares of drug developer Amarin AMRN.O rise 2.1% to $15 premarket

** Co says new analyses reinforce benefits of Vascepa, its heart drug used to lower the risk of serious heart events in high‑risk patients

** Icosapent ethyl targets high triglycerides, a type of blood fat that can raise heart attack and stroke risk even when cholesterol is controlled - AMRN

** Co says secondary analysis of its study showed fewer heart‑related events when the drug was added to standard statin therapy in the highest‑risk patients

** Updated U.S. cardiology guidelines flagged high triglycerides as an ongoing heart risk and recommend treatments beyond statins for some patients, while cautioning against routine fibrate use - AMRN

** Drug is sold as Vascepa in the U.S. and Vazkepa in Europe and is approved in nearly 100 markets, co says

** As of last close, stock up ~5% YTD

(Reporting by Sahil Pandey in Bengaluru)

((Sahil.Pandey@thomsonreuters.com))

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment